Four Leading Trial Attorneys Inducted Into 2026 Hall of Fame

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Four prominent trial attorneys—Placitella, Rosner, Eglet, and Kline—inducted into 2026 Trial Lawyer Hall of Fame for their decades of litigation experience and significant courtroom achievements.

Four Leading Trial Attorneys Inducted Into 2026 Hall of Fame

The Trial Lawyer Hall of Fame has announced the 2026 induction of four prominent litigators: Christopher M. Placitella, Daniel E. Rosner, Robert T. Eglet, and Thomas R. Kline. The honorees will receive recognition at the MTMP Spring 2026 mass torts conference in Las Vegas, scheduled for April 15-17. Each inductee brings decades of trial experience and has established a significant track record in complex civil litigation.

The four attorneys are being recognized for their substantial contributions to the civil justice system and their achievements in obtaining notable courtroom verdicts and settlements throughout their careers. Their inclusion in the 2026 class reflects their standing among peers and their influence in advancing trial practice at both state and federal levels. The Hall of Fame selection process identifies trial lawyers who have demonstrated exceptional skill, integrity, and professional achievement.

This year's induction class underscores the continued prominence of experienced trial counsel in mass tort litigation and complex civil disputes. The recognition serves to acknowledge their professional accomplishments and their roles in shaping contemporary legal practice within the trial bar community.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 18

Related Coverage

Benzinga

J&J and Protagonist Win FDA Approval for Oral Psoriasis Drug, Challenging AbbVie's Market Dominance

FDA approves Icotyde for psoriasis, triggering $50M payment to Protagonist. Market reacts with AbbVie stock falling 5.20% amid competitive pressure.

JNJABBVPTGX
GlobeNewswire Inc.

Surgical Stapling Devices Market to Nearly Double to $10.1B by 2035

Global surgical stapling devices market valued at $5.47B in 2025, projected to reach $10.14B by 2035, growing 7.2% annually driven by minimally invasive procedures and obesity.

JNJMDTISRG
GlobeNewswire Inc.

Mestag Therapeutics Secures $40M to Advance FAP-Targeted Cancer Immunotherapy

Mestag Therapeutics closes $40M financing and appoints leadership to advance FAP-targeted cancer immunotherapy MST-0312 into Phase 1 clinical trials.

JNJ
Investing.com

Defensive Sectors Flash Mixed Signals as Volatility Spikes

Defensive sectors show conflicting technical signals: Utilities strengthen while Consumer Staples weaken and Health Care forms bearish patterns, creating mixed market outlook.

JNJWMTNVDA
GlobeNewswire Inc.

BIO-Europe Spring 2026 Poised for Record Dealmaking as 3,700+ Leaders Convene

BIO-Europe Spring 2026 in Lisbon expects 3,700+ attendees, 20,000+ meetings, and robust partnering activity as global biopharma industry seeks strategic deals and investment opportunities.

JNJLLYNVO
The Motley Fool

SCHD vs HDV: Which Dividend ETF Wins for Income Investors?

SCHD offers lower costs (0.06%) and higher yield (3.4%) with 101 holdings, while HDV delivers stronger recent returns (17.6%) with 74 concentrated stocks. Choose based on cost preference and risk tolerance.

JNJXOMCVX